Keyword: Cambridge, Massachusetts
Beijing’s CANbridge Life Sciences, developing Western drug candidates in China and Asia, brought on Pfizer’s May Orfali to be chief medical officer.
Eisai's new drug discovery facility will focus on immune-driven Alzheimer’s and receive more than $100 million to get up and running.
InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.
Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.
Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.
Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief.